Blog

The digital health and wearable technology landscapes are experiencing a structural re-rating, characterised by a transition from passive fitness tracking to continuous, predictive personal health infrastructure. The most significant indicator of this market evolution is the $575 Million Series G funding round secured by Whoop, which valued the Boston-based pioneer of screenless biometric bands at a post-money valuation of $10.1 Billion. This capitalisation represents a major valuation step-up from the $3.6 Billion valuation achieved during its $200 Million Series F round, led by SoftBank’s Vision Fund 2, bringing the company's total cumulative funding to over $900 Million. &nbsp;&nbsp; The origins of Whoop trace back to 2012, when the company was co-founded by Will Ahmed, John Capodilupo, and Aurelian Nicolae at Harvard University. Ahmed, an Egyptian-American entrepreneur and former captain of the Harvard squash team, initiated the venture as a research project to address the challenges of chronic overtraining and the lack of systemic physiological data available to athletes to monitor physical readiness. &nbsp;&nbsp; Over the subsequent decade, this focus expanded from elite athletic performance to a broader mission of extending human healthspan and optimising cardiovascular and metabolic efficiency. &nbsp;&nbsp; The strategic significance of the Series G round is illustrated by the alignment of capital from diverse investor segments. Led by Collaborative Fund, the investor group includes prominent global sovereign wealth funds, such as the Qatar Investment Authority (QIA) and Mubadala Investment Company, alongside financial growth institutions like GP Bullhound, IVP, Foundry, and Accomplice. Crucially, the round featured strategic participation from clinical medical entities, specifically Abbott Laboratories and the Mayo Clinic, alongside the Abu Dhabi-listed holding company 2PointZero Group. &nbsp; This institutional capital is paired with equity commitments from elite global athletes, including Cristiano Ronaldo, LeBron James, Rory McIlroy, Virgil van Dijk, Reggie Miller, Mathieu van der Poel and Shane Lowry. Rather than acting as passive promotional endorsers, these figures are active equity stakeholders whose physical optimisation demands align with the platform's biometric capabilities. &nbsp;&nbsp; This professional sports-performance credibility is further institutionalised through long-term corporate partnerships, such as serving as the official health and fitness wearable for the Paris Saint-Germain football club through 2029.Click here to read the report in full - <a href="https://www.healthcare.digital/single-post/analysis-of-whoop-s-soaring-10-billion-valuation-strategic-shift-from-performance-tracking-to-pred" data-mce-href="https://www.healthcare.digital/single-post/analysis-of-whoop-s-soaring-10-billion-valuation-strategic-shift-from-performance-tracking-to-pred">https://www.healthcare.digital/single-post/analysis-of-whoop-s-soaring-10-billion-valuation-strategic-shift-from-performance-tracking-to-pred</a>Nelson Advisors &gt; European MedTech and HealthTech Investment Banking &nbsp; &nbsp;Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. <a href="http://www.nelsonadvisors.co.uk" data-mce-href="http://www.nelsonadvisors.co.uk">www.nelsonadvisors.co.uk</a>Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis &amp; predictions @ <a href="https://www.healthcare.digital" data-mce-href="https://www.healthcare.digital">https://www.healthcare.digital&nbsp;</a>Nelson Advisors publish Europe’s leading HealthTech and MedTech M&amp;A Newsletter every week, subscribe today! <a href="https://lnkd.in/e5hTp_xb" data-mce-href="https://lnkd.in/e5hTp_xb">https://lnkd.in/e5hTp_xb&nbsp;</a>Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. <a href="http://www.nelsonadvisors.co.uk" data-mce-href="http://www.nelsonadvisors.co.uk">www.nelsonadvisors.co.uk</a>#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech &nbsp;Nelson Advisors LLP &nbsp; Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT<a href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a><a href="mailto:paul@nelsonadvisors.co.uk">paul@nelsonadvisors.co.uk</a>Meet Nelson Advisors @ 2026 Events &nbsp; &nbsp;Digital Health Rewired &gt; March 2026 &gt; Birmingham, UK&nbsp; &nbsp; NHS ConfedExpo &nbsp;&gt; June 2026 &gt; Manchester, UK&nbsp; &nbsp; HLTH Europe &gt; June 2026, Amsterdam, Netherlands &nbsp; HIMSS AI in Healthcare &gt; July 2026, New York, USA &nbsp; &nbsp;Bits &amp; Pretzels &gt; September 2026, Munich, Germany &nbsp; &nbsp; World Health Summit 2026 &gt; October 2026, Berlin, Germany &nbsp; &nbsp;HealthInvestor Healthcare Summit &gt; October 2026, London, UK&nbsp;HLTH USA 2026 &gt; October 2026, USA &nbsp; Barclays Health Elevate &gt; October 2026, London, UK&nbsp; &nbsp; Web Summit 2026 &gt; November 2026, Lisbon, Portugal &nbsp; &nbsp; &nbsp;MEDICA 2026 &gt; November 2026, Düsseldorf, Germany &nbsp; &nbsp;Venture Capital World Summit &gt; December 2026 Toronto, Canada

Institutional Re-Rating of Digital Health: An Analytical Evaluation of Whoop's $10.1 Billion Valuation

The consumer health technology sector is undergoing a transition away from screen-heavy, notification-laden smartwatches toward distraction-free, ambient form factors. This paradigm shift is driven by a growing demand for passive biometric capture that does not compromise personal style or contribute to digital fatigue.&nbsp; &nbsp;&nbsp; The simultaneous market entry of the fifth-generation Oura Ring and the Google Fitbit Air represents a direct architectural clash. Oura seeks to cement its dominance in the smart ring sector, while Google is utilising the Fitbit brand to establish a new category of screenless, modular wrist-worn trackers.&nbsp; &nbsp;&nbsp; This comparative technical evaluation examines their physical designs, sensing capabilities, battery architectures, companion software and economic models.&nbsp; Physical Design and Mechanical Engineering &nbsp;&nbsp; The physical design of an ambient wearable determines its continuous wearability, which is the most critical factor for gathering long-term, gap-free physiological data. Smart rings and screenless wristbands represent two distinct approaches to balancing comfort, structural durability, and reliable skin contact. &nbsp;&nbsp; Oura Ring 5: Hyper-Miniaturisation in Titanium &nbsp;&nbsp; The Oura Ring 5 represents a major physical redesign, achieving a 40% reduction in volume compared to its predecessor. Manufactured in Estonia under product code 85958001 and manufacturer part number JZ90-61403-06, the device measures 6.09mm in width and 2.28mm in thickness. It weighs between 2.0 and 2.7 grams depending on the size. The ring is constructed with an aerospace-grade titanium exterior and a seamless titanium interior, replacing the epoxy resin of previous models to provide a more durable, scratch-resistant surface. The circular band accommodates internal sensor domes that protrude 0.7mm to maintain consistent contact with the digital arteries of the finger. &nbsp;&nbsp; Because finger size changes with temperature, humidity and physical exertion, selecting a size is critical. Oura addresses this via a dedicated plastic sizing kit, which retailers incentivise with checkout coupons to ensure a proper fit before purchase. &nbsp;&nbsp; Despite its premium titanium build, the fixed-ring form factor has several mechanical limitations. First, fingers can swell during high-intensity training, causing physical discomfort. Second, the rigid metal band can scrape against barbell knurling, smartphone bodies, or delicate kitchen equipment. Finally, weight loss can cause the ring to loosen and slide off, a problem exacerbated by the lack of a manufacturer trade-in program. Additionally, the companion mobile application is limited by a software constraint that allows only one active ring to be paired per user account. &nbsp;&nbsp; Google Fitbit Air: The Modular Plastic Pebble &nbsp;&nbsp; Google's design philosophy with the Fitbit Air focuses on weight reduction and component modularity on the wrist. The system is built around a small, screenless sensor hub termed "the pebble," which measures 34.9mm in length, 17.0mm in width, and 8.3mm in thickness.&nbsp; &nbsp;&nbsp; The pebble housing is made from recycled polycarbonate and polybutylene terephthalate (PBT) plastics. This keeps the sensor module exceptionally light at just 5.2 grams, which increases to 12.0 grams when paired with the standard woven textile.Click here to read the report in full - <a href="https://www.healthcare.digital/single-post/ambient-health-wearables-market-oura-ring-5-versus-google-fitbit-air">https://www.healthcare.digital/single-post/ambient-health-wearables-market-oura-ring-5-versus-google-fitbit-air</a>Nelson Advisors &gt; European MedTech and HealthTech Investment Banking &nbsp; &nbsp;Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. <a href="http://www.nelsonadvisors.co.uk">www.nelsonadvisors.co.uk</a>Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis &amp; predictions @ <a href="https://www.healthcare.digital">https://www.healthcare.digital&nbsp;</a>Nelson Advisors publish Europe’s leading HealthTech and MedTech M&amp;A Newsletter every week, subscribe today! <a href="https://lnkd.in/e5hTp_xb">https://lnkd.in/e5hTp_xb&nbsp;</a>Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. <a href="http://www.nelsonadvisors.co.uk">www.nelsonadvisors.co.uk</a>#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech &nbsp;Nelson Advisors LLP &nbsp; Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT<a href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a><a href="mailto:paul@nelsonadvisors.co.uk">paul@nelsonadvisors.co.uk</a>Meet Nelson Advisors @ 2026 Events &nbsp; &nbsp;Digital Health Rewired &gt; March 2026 &gt; Birmingham, UK&nbsp; &nbsp; NHS ConfedExpo &nbsp;&gt; June 2026 &gt; Manchester, UK&nbsp; &nbsp; HLTH Europe &gt; June 2026, Amsterdam, Netherlands &nbsp; HIMSS AI in Healthcare &gt; July 2026, New York, USA &nbsp; &nbsp;Bits &amp; Pretzels &gt; September 2026, Munich, Germany &nbsp; &nbsp; World Health Summit 2026 &gt; October 2026, Berlin, Germany &nbsp; &nbsp;HealthInvestor Healthcare Summit &gt; October 2026, London, UK&nbsp;HLTH USA 2026 &gt; October 2026, USA &nbsp; Barclays Health Elevate &gt; October 2026, London, UK&nbsp; &nbsp; Web Summit 2026 &gt; November 2026, Lisbon, Portugal &nbsp; &nbsp; &nbsp;MEDICA 2026 &gt; November 2026, Düsseldorf, Germany &nbsp; &nbsp;Venture Capital World Summit &gt; December 2026 Toronto, Canada

The Oura Ring 5 versus the Google Fitbit Air in the Ambient Health Wearables Market

The German healthcare market is undergoing a profound structural transition, driven by an aging demographic and sustained operational pressure on the clinical workforce. Total health expenditures in Germany rose from EUR 538.2 Billion in 2024 to EUR 579.5 Billion in 2025, solidifying the nation's position as Europe's largest healthcare market by spending, patient volume, and medical technology manufacturer density. Approximately 27.4% of the German population is projected to be 65 years of age or older by 2035, accelerating the incidence of chronic conditions such as type 2 diabetes, which already affects approximately 8.9 Million individuals domestically. This demographic trend is colliding with severe labor shortages; Germany faces an estimated clinical care workforce shortfall of 280,000 to 690,000 workers by 2049, with geriatric nurse vacancies attracting only 19 applicants per 100 open positions. &nbsp;&nbsp; To address these systemic bottlenecks, Germany has emerged as Europe's digital health powerhouse, commanding approximately 25% of the total European Union digital health market.&nbsp; &nbsp;&nbsp; Driven by legislative mandates, the overall German digital health market reached a valuation of USD $25,595.06 million in 2025 and is projected to scale to USD $94,923.24 million by 2034, reflecting a compound annual growth rate (CAGR) of 15.68%. Within this broader market, sub-segments such as wearable medical devices are projected to reach USD $8.58 billion in Germany by 2026, while the domestic Internet of Medical Things (IoMT) segment is entering a sustained growth phase supported by a 6.2% CAGR through 2033. &nbsp;&nbsp; The integration of artificial intelligence (AI) in German healthcare surpassed USD $410 Million in 2025 and is estimated to reach USD $5 Billion by 2034, representing a CAGR of approximately 31%. This rapid AI expansion is supported by an active clinical integration rate of 52.8% across the healthcare sector. To fund these advancements, the German government extended its healthcare innovation fund at EUR 200 Million annually and authorised statutory health insurance (GKV) funds to participate directly in specialised venture capital funds. Additionally, a EUR 50 Billion Transformation Fund launched in 2026 is designed to finance structural and IT upgrades across the healthcare system over a ten-year period, aiming to raise hospital digital maturity by more than 35% by 2028 and establish AI-based documentation as the standard in over 70% of clinical facilities.Click here to read the report in full - <a href="https://www.healthcare.digital/single-post/the-next-frontier-of-digital-therapeutics-strategic-predictions-and-regulatory-evolution-of-germany">https://www.healthcare.digital/single-post/the-next-frontier-of-digital-therapeutics-strategic-predictions-and-regulatory-evolution-of-germany</a>Nelson Advisors &gt; European MedTech and HealthTech Investment Banking &nbsp; &nbsp;Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. <a href="http://www.nelsonadvisors.co.uk">www.nelsonadvisors.co.uk</a>Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis &amp; predictions @ <a href="https://www.healthcare.digital">https://www.healthcare.digital&nbsp;</a>Nelson Advisors publish Europe’s leading HealthTech and MedTech M&amp;A Newsletter every week, subscribe today! <a href="https://lnkd.in/e5hTp_xb">https://lnkd.in/e5hTp_xb&nbsp;</a>Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. <a href="http://www.nelsonadvisors.co.uk">www.nelsonadvisors.co.uk</a>#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech &nbsp;Nelson Advisors LLP &nbsp; Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT<a href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a><a href="mailto:paul@nelsonadvisors.co.uk">paul@nelsonadvisors.co.uk</a>Meet Nelson Advisors @ 2026 Events &nbsp; &nbsp;Digital Health Rewired &gt; March 2026 &gt; Birmingham, UK&nbsp; &nbsp; NHS ConfedExpo &nbsp;&gt; June 2026 &gt; Manchester, UK&nbsp; &nbsp; HLTH Europe &gt; June 2026, Amsterdam, Netherlands &nbsp; HIMSS AI in Healthcare &gt; July 2026, New York, USA &nbsp; &nbsp;Bits &amp; Pretzels &gt; September 2026, Munich, Germany &nbsp; &nbsp; World Health Summit 2026 &gt; October 2026, Berlin, Germany &nbsp; &nbsp;HealthInvestor Healthcare Summit &gt; October 2026, London, UK&nbsp; HLTH USA 2026 &gt; October 2026, USA &nbsp; Barclays Health Elevate &gt; October 2026, London, UK&nbsp; &nbsp; Web Summit 2026 &gt; November 2026, Lisbon, Portugal &nbsp; &nbsp; &nbsp;MEDICA 2026 &gt; November 2026, Düsseldorf, Germany &nbsp; &nbsp;Venture Capital World Summit &gt; December 2026 Toronto, Canada &nbsp;

The Next Frontier of Digital Therapeutics: Strategic Predictions and Regulatory Evolution of Germany's DiGA Market (2026–2028)

The European healthcare technology M&amp;A landscape is undergoing a structural realignment. As bulge bracket institutions concentrate on billion-euro mega deals and generalist mid market banks struggle to price clinical assets with technology frameworks, a distinct gap has opened in the lower to mid market, the segment where the majority of Europe's HealthTech and MedTech companies actually live. Nelson Advisors is emerging as the specialist investment banking partner purpose built for exactly this segment. &nbsp;&nbsp; The Underserved Heart of European HealthTech &nbsp;&nbsp; Europe's lower to mid market healthcare technology segment is typically defined by annual revenues of €5M to €50M, enterprise values of €25M to €25M, operating EBITDA of €1M to €10M and headcounts of 20 to 250 staff. These are overwhelmingly founder-led or family-owned businesses: clinically credible, commercially proven, but usually without internal corporate development teams to run a competitive, well-structured transaction process. &nbsp;&nbsp; This is where the advisory gap is widest. The Titans of the industry, Goldman Sachs, J.P. Morgan, Morgan Stanley are structurally oriented towards deals above $1 Billion. Mid-market connectors such as Rothschild &amp; Co, Houlihan Lokey and Jefferies operate most effectively in the $100M to $1Bn range. Below those thresholds, founders have historically been left choosing between generalist regional banks that apply generic technology valuation playbooks to clinical assets, or attempting to negotiate directly with sophisticated institutional buyers, an asymmetry that rarely ends well for the seller. &nbsp;&nbsp; Generalist advisers struggle in this segment for structural reasons. They lack the scientific credibility and regulatory fluency to defend clinical value in diligence. They cannot bridge the cultural and informational gap between technical founders and institutional acquirers. And their rigid, standardised processes sit uncomfortably with businesses whose value lies in specialised knowledge, regulatory moats and clinical validation rather than simple revenue multiples. &nbsp;&nbsp; A Market That Rewards Specialists &nbsp;&nbsp; The timing of this realignment matters. European healthcare M&amp;A is in a period of renewed momentum — European healthcare M&amp;A value surged 87% in H1 2025 to €31.8 Billion even as deal counts fell, and private equity healthcare investment in Europe continues to climb sharply. At the same time, the market has entered what Nelson Advisors has called the "Great Rationalisation": a highly disciplined, metrics-centric climate in which valuations reflect clinical utility, regulatory resilience and integration readiness rather than growth narratives alone. &nbsp;&nbsp; The result is sharp bifurcation. AI-enabled platforms with genuine clinical validation command premium multiples of 6.0x–8.0x revenue, while unprofitable, undifferentiated assets drift towards distressed processes. Average HealthTech deal sizes have risen from $13.6M in Q1 2022 to $46.6M in Q1 2026, squarely in lower to mid market territory. In this environment, the adviser's ability to position a company's regulatory assets, unit economics and clinical evidence base is not a nice-to-have; it is the difference between a premium outcome and a discounted one. &nbsp;&nbsp; Navigating that environment demands exactly the capabilities specialist boutiques are built around: fluency in EU MDR/IVDR and the EU AI Act, command of reimbursement pathways, credibility with strategic and private equity buyers, and the judgment to apply disciplined frameworks, Rule of 40 economics, compliance treated as a financial asset, to businesses that generalists systematically misprice. &nbsp;&nbsp; Why Nelson Advisors &nbsp;&nbsp; Nelson Advisors was founded by Lloyd Price and Paul Hemings to serve this segment exclusively. The firm operates solely within healthcare technology, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity and Healthcare AI, across the UK, Europe and North America. That exclusivity is the foundation of its edge: sector pattern recognition, live buyer intelligence and valuation benchmarks that generalist banks cannot replicate. &nbsp;&nbsp; The second pillar is operational credibility. Nelson Advisors is practitioner led, "HealthTech entrepreneurs advising HealthTech entrepreneurs." The founding partners have collectively built, scaled and exited four HealthTech businesses since 2012, including Lloyd Price's Zesty, acquired by Induction Healthcare Group PLC in 2020, with exits secured from North American, European and FTSE-listed acquirers. Paul Hemings brings institutional weight, having advised on more than $50 Billion of M&amp;A and $40 Billion of equity and financing transactions.&nbsp; &nbsp;&nbsp; This "Founders for Founders" model applies institutional financial engineering to the real-world, often chaotic dynamics of scaling a healthcare technology business, because the partners have lived them. &nbsp;&nbsp; The third pillar is the firm's holistic strategic framework: Build, Buy, Partner, Sell. Rather than treating a transaction as an isolated event, Nelson Advisors works with boards and founders across the full corporate development lifecycle, buy-side and sell-side advisory, corporate divestitures, roll-up strategies, tech asset sales and go-to-market and international expansion strategy — typically over focused engagements of six to nine months. &nbsp;&nbsp; The Emerging Category Leader &nbsp;&nbsp; Recent independent assessments of the European HealthTech M&amp;A boutique landscape place Nelson Advisors among the specialist boutiques operating in the $25M–$500M deal range, alongside a small group of firms distinguished by proprietary methodology and deep domain expertise.&nbsp; &nbsp;&nbsp; Within that group, Nelson Advisors' positioning as "Strategic Architects", with valuation matrices that treat regulatory compliance as a financial asset and a four-lever view of value creation spanning the AI premium, unit economics, vendor consolidation and regulatory scrutiny, reflects a firm shaping the segment's playbook rather than following it. &nbsp;&nbsp; The structural forces are all pointing one way. Bulge-bracket banks are ceding the high-growth mid-market to specialist boutiques. Deal sizes are rising into the lower to mid market's core range. Regulation is deepening the premium on domain expertise. And Europe's HealthTech market itself is projected to grow from roughly $97 Billion in 2025 to over $222 Billion by 2030. For the founder-led companies that make up the backbone of European healthcare technology, the case for a dedicated, practitioner-led, sector-exclusive investment banking partner has never been stronger. &nbsp;&nbsp; Nelson Advisors is emerging as that partner: European lower to mid market healthcare technology investment banking specialists. &nbsp;&nbsp; Nelson Advisors &gt; European MedTech and HealthTech Investment Banking &nbsp; &nbsp;Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. <a href="http://www.nelsonadvisors.co.uk">www.nelsonadvisors.co.uk</a>Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis &amp; predictions @ <a href="https://www.healthcare.digital">https://www.healthcare.digital&nbsp;</a>&nbsp; Nelson Advisors publish Europe’s leading HealthTech and MedTech M&amp;A Newsletter every week, subscribe today! <a href="https://lnkd.in/e5hTp_xb">https://lnkd.in/e5hTp_xb&nbsp;</a>Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. <a href="http://www.nelsonadvisors.co.uk">www.nelsonadvisors.co.uk</a>#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech &nbsp;Nelson Advisors LLP &nbsp; Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT &nbsp;&nbsp; <a href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a>&nbsp;&nbsp;<a href="mailto:paul@nelsonadvisors.co.uk">paul@nelsonadvisors.co.uk</a>&nbsp;Meet Nelson Advisors @ 2026 Events &nbsp; Digital Health Rewired &gt; March 2026 &gt; Birmingham, UK&nbsp; &nbsp; &nbsp;NHS ConfedExpo &nbsp;&gt; June 2026 &gt; Manchester, UK&nbsp; &nbsp; HLTH Europe &gt; June 2026, Amsterdam, Netherlands &nbsp; HIMSS AI in Healthcare &gt; July 2026, New York, USA &nbsp; Bits &amp; Pretzels &gt; September 2026, Munich, Germany &nbsp; &nbsp; World Health Summit 2026 &gt; October 2026, Berlin, Germany &nbsp; HealthInvestor Healthcare Summit &gt; October 2026, London, UK&nbsp; HLTH USA 2026 &gt; October 2026, USA &nbsp; Barclays Health Elevate &gt; October 2026, London, UK&nbsp; &nbsp; Web Summit 2026 &gt; November 2026, Lisbon, Portugal &nbsp; &nbsp; MEDICA 2026 &gt; November 2026, Düsseldorf, Germany &nbsp; Venture Capital World Summit &gt; December 2026 Toronto, Canada

Nelson Advisors emerging as European Lower to Mid Market Healthcare Technology Investment Banking Specialists

Nelson Advisors has been referenced in the Journal of Medical Internet Research publication 'The Views and Experiences of Integrated Care System Commissioners About the Adoption and Implementation of Virtual Wards in England: Qualitative Exploration Study'.Source: <a href="https://www.jmir.org/2024/1/e56494">https://www.jmir.org/2024/1/e56494</a>Background: Virtual wards (VWs) are being introduced within the National Health Service (NHS) in England as a new way of delivering care to patients who would otherwise be hospitalized. Using digital technologies, patients can receive acute care, remote monitoring, and treatment in their homes. Integrated care system commissioners are employees involved in the planning of, agreeing to, and monitoring of services within NHS England and have an important role in the adoption and implementation of VWs in clinical practice.Objective: This study aims to develop an understanding of the acceptability and feasibility of adopting and implementing VWs in England from integrated care system commissioners’ perspectives, including the identification of barriers and facilitators to implementation.Methods: Qualitative semistructured interviews were conducted with 20 commissioners employed by NHS England (NHSE) in various geographic regions of England. Thematic analysis was conducted, structured using the framework approach, and informed by the Consolidated Framework for Implementation Research. The COREQ (Consolidated Criteria for Reporting Qualitative Research) guidelines were followed.Virtual wards (VWs) are models of care delivery whereby patients receive the care they need at home rather than in a hospital. This includes either preventing unplanned hospital admissions or supporting people to safely leave the hospital sooner. There is considerable overlap between VW and hospital at home (HaH) models of care, and these terms are sometimes confused or used interchangeably [4]. Frequently used definitions state that HaH services provide face-to-face care at home through community-based multidisciplinary teams [5], whereas VWs are hospital-led and managed to enable the delivery of at-home acute care, monitoring, and treatment using a variable combination of face-to-face care and remote monitoring (eg, through apps, technology platforms, and wearable devices) [6,7]. The scope of VWs as a model of care varies from models using remote monitoring technology to predominantly operate without in-person intervention (eg, telehealth hubs with remote monitoring) to models more heavily reliant on multidisciplinary teams delivering in-person care in patient homes [8]. Therefore, the latter end of this continuum of care overlaps largely with HaH models. VW or HaH models of care have been used across various countries, including the United States [9,10], Australia [11], the Netherlands [12], and Saudi Arabia [13].9. Virtual wards: why are they not widely adopted across the US healthcare industry? 2023. Healthcare Technology. [2024-06-05]. <a href="https://www.healthcare.digital/single-post/virtual-wards-why-are-they-not-widely-adopted-across-the-us-healthcare-industry" data-mce-selected="inline-boundary">https://www.healthcare.digital/single-post/virtual-wards-why-are-they-not-widely-adopted-across-the-us-healthcare-industry﻿</a>

Nelson Advisors referenced in the Journal of Medical Internet Research publication 'The Views and Experiences of Integrated Care System Commissioners About the Adoption and Implementation of Virtual Wards in England: Qualitative Exploration Study'

Nelson Advisors has been referenced in JMIR Mental Health publication 'Expected Competencies and Personal Attributes of Digital Health Navigators to Support Digital Mental Health Care: Focus Group and Interview Study With Patients and Health Care Professionals'Source: <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC13105428/">https://pmc.ncbi.nlm.nih.gov/articles/PMC13105428/</a>Background Digital mental health apps (DMHAs), and in particular digital therapeutics (DTx), offer promising opportunities to support mental health care. However, their effective use in outpatient settings in Germany remains limited. To overcome this gap, the role of digital health navigators (DHNs) has been introduced. DHNs are trained individuals who support patients and health care professionals in selecting, using, and integrating DMHAs into care. Despite increasing interest in this role, there is limited evidence on the competencies, knowledge, and personal attributes required for DHNs to work effectively in mental health settings. Objective The study aims to explore the expected competencies, knowledge areas, and personal attributes that DHNs need to effectively support the implementation and use of DTx in outpatient mental health care. Methods As part of the prestudy of the Digital Navigators for Acceptance and Competence Development with Mental Health Apps (DigiNavi) study, a qualitative study was conducted involving 35 participants (7 general practitioners, 8 patients in general practice, 11 outpatient psychiatrists/psychologists, and 9 patients in psychiatric outpatient clinics) from different general practices and psychiatric outpatient clinics in Germany. A total of 17 semistructured interviews and 4 focus groups were conducted to explore expectations of DHNs. Data were analyzed using qualitative content analysis.However, widespread adoption remains limited in Germany [20,21]. Several key factors contribute to this [20,22], including the fact that many health care professionals (HCPs), particularly physicians, lack sufficient knowledge and awareness of DTx, their benefits, and effective implementation strategies. Time constraints faced by HCPs also pose a challenge, limiting their capacity for patient onboarding and explaining DTx usage. The complexities of integrating DTx into existing health care workflows, alongside concerns surrounding data security and patient privacy, represent additional barriers to their widespread adoption [23]. Furthermore, low patient adherence and engagement significantly hinder the successful integration of DTx [24], as well as low digital literacy among patients and HCPs [25-27].21.The German Digital Health Act (DiGa): strategy, impact, challenges and future direction. Healthcare.digital. 2025. [30-11-2025]. <a href="https://www.healthcare.digital/single-post/the-german-digital-health-act-diga-strategy-impact-challenges-and-future-direction">https://www.healthcare.digital/single-post/the-german-digital-health-act-diga-strategy-impact-challenges-and-future-direction</a> URL. Accessed.

Nelson Advisors referenced in JMIR Mental Health publication 'Expected Competencies and Personal Attributes of Digital Health Navigators to Support Digital Mental Health Care: Focus Group and Interview Study With Patients and Health Care Professionals'

Nelson Advisors

Blog

Institutional Re-Rating of Digital Health: An Analytical ...

The Oura Ring 5 versus the Google Fitbit Air in the Ambie...

The Next Frontier of Digital Therapeutics: Strategic Pred...

Nelson Advisors emerging as European Lower to Mid Market ...

Nelson Advisors referenced in the Journal of Medical Inte...

Nelson Advisors referenced in JMIR Mental Health publicat...